Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
Hiroaki AkamatsuEriko MurakamiJun OyanagiRyota ShibakiTakahiro KakiEri TakaseMasanori TanakaYuhei HarutaniNao YamagataYuka OkudaKatsuyuki FurutaTakeya SugimotoShunsuke TeraokaAtsushi HayataNahomi TokudomeYuichi OzawaKeita MoriYasuhiro KohNobuyuki YamamotoPublished in: The oncologist (2019)
Although the predictive value of immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs) has been suggested by several studies, it has not been elucidated whether irAEs also play a significant role even in responders. This study showed that more than 60% of responders had irAEs. It demonstrated the strong correlation between irAEs and efficacy even in responders. Investigation into the significance of irAEs in responders will contribute to the establishment of optimal administration of ICI.